Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770397 | 0.87 | ALDH1A1 (0.36) | RBP4ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL770696 | 0.87 | MEN1 (0.38) | ALDH1A1POLBCNR1ITGB3ITGA2B | |
| SCHEMBL771656 | 0.87 | MAPK1 (0.36) | ALDH1A1POLBNPC1SMN1; SMN2MAPT | |
| SCHEMBL770768 | 0.85 | ITGB3 (0.41) | ALDH1A1ITGB3ITGA2BNPC1SMN1; SMN2 | |
| SCHEMBL770303 | 0.85 | PDE4B (0.47) | ALDH1A1POLBCNR1RAB9APDE4B | |
| SCHEMBL770381 | 0.85 | ITGB3 (0.41) | ALDH1A1POLBITGB3ITGA2BNPC1 | |
| SCHEMBL770075 | 0.85 | ALDH1A1 (0.42) | ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL769789 | 0.84 | NPC1 (0.42) | ALDH1A1POLBITGB3ITGA2BNPC1 | |
| SCHEMBL771618 | 0.84 | CPN1 (0.35) | ALDH1A1POLBSMN1; SMN2MAPTTDP1 | |
| SCHEMBL771592 | 0.84 | ALDH1A1 (0.42) | ALDH1A1POLBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2439202-B1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SALVAT LAB SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | RBP4 1300/4885ALDH1A1 142/4885POLB 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.